NORTH AMERICAN SCIENTIFIC INC.Symbol: NASI (1) (NetWare Asynchronous Service Interface) A protocol from Novell for connecting to modems in a communications server. It was derived from the NCSI protocol. NASI provides more advanced features than the common int 14 (interrupt 14) method. Exchange: NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). Close: 10 1/8 1-WK % Chg: 16.9% Business Overview North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Scientific (NASI) markets radiolsotopic products, including brachytherapy seeds (a treatment involving implanting radioactive material radioactive material Radiation A substance that contains unstable–radioactive–atoms that give off radiation as they decay. See Radioactive decay. in cancer patients to target tumors) and radiopharmaceuticals, for the treatment of diseases such as cancer and heart disease. A deal with medical product distributor, Mentor Corp., to market its IoGold and PdGold products, which treat early stages of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , currently comprise approximately 80% of the company's revenues. Through its acquisition in October 2000 of development-stage firm, Theseus Imaging, the company is developing the product, Apomate, that is designed to detect cell death either through apoptosis or cell necrosis, which is used to determine whether a patient is responding to chemotherapy or rejecting a cardiac transplant. Income Statment LTM 1999 Summary Revenue (millions) $17.5 $12.8 Hqtrs: Chatsworth Gross Profit (millions) 11.7 8.2 CEO: L. Michaei Cutrer Operating Income [*] (millions) (3.9) 4.8 Market Cap: $102.1 million Net Income (millions) (6.0) 3.4 Dividend Yield: N/A Earnings Per Share ($0.87) $0.47 P/E Ratio: N/A (*.)Includes $11.4 million expense relating to purchased in-process research and developemnt. LTM - Latest 12 months |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion